Blood-thinning drugs designed to cut stroke risk may actually increase it

Scientists call for caution in prescribing anticoagulants after some patients with other conditions found to suffer more strokesBlood-thinning drugs may increase rather than cut the risk of stroke in some people over 65 who have an irregular heartbeat and also chronic kidney disease, according to a new study.The researchers are calling on doctors to be more cautious in prescribing the drugs, called anticoagulants, until there has been more research.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Medical research Stroke Drugs Health Science Society Doctors Source Type: news

Related Links:

Non valvular atrial fibrillation (NVAF) is highly prevalent among chronic kidney disease (CKD) patients in whom it portends increased risk for subsequent stroke or systemic thromboembolic events. For these high risk patients oral anticoagulation is recommended, after proper assessment of both thromboembolic and bleeding risk is accurately ascertained.However, current NVAF risk scores are inadequate for use in CKD subjects, since they do not take into account the occurrence and the degree of renal function impairment.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Authors: Kim HJ, Oh YN, Ju MH, Kim JB, Jung SH, Chung CH, Lee JW, Choo SJ Abstract Background: We reviewed our experience with on-pump beating (OPB) heart coronary artery bypass grafting (CABG) to evaluate the impacts of obviating aortic cross-clamping and cardioplegic arrest on clinical outcomes compared with conventional CABG (C-CABG). Methods: Between 2006 and 2012, elective isolated cardiopulmonary bypass (CPB)-assisted CABG was consecutively performed in 645 patients (mean patient age 63.3±9.1 years, 471 women) with 254 (39.4%) undergoing OPB-CABG and 391 (60.6%) undergoing C-CABG. The early and lon...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Publication date: September 2018Source: Clinica Chimica Acta, Volume 484Author(s): Gjin NdrepepaAbstractUric acid (UA) is an end product of purine metabolism in humans and great apes. UA acts as an antioxidant and it accounts for 50% of the total antioxidant capacity of biological fluids in humans. When present in cytoplasm of the cells or in acidic/hydrophobic milieu in atherosclerotic plaques, UA converts into a pro-oxidant agent and promotes oxidative stress and through this mechanism participates in the pathophysiology of human disease including cardiovascular disease (CVD). Most epidemiological studies but not all of ...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Conclusions: The incidence of death without stroke was 9-fold higher than that of stroke, leading to biased estimates of stroke risk with traditional time-to-event methods. Statistical methods that appropriately account for competing risks should be used to mitigate this bias.
Source: Circulation: Cardiovascular Quality and Outcomes - Category: Cardiology Authors: Tags: Atrial Fibrillation, Epidemiology, Primary Prevention, Cerebrovascular Disease/Stroke Original Articles Source Type: research
Publication date: May 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 3Author(s): Forrest H. NielsenAlthough official magnesium (Mg) dietary reference intakes are open to question, a significant number of adults likely have intakes that are in the range of 50%-99% of the requirement. This moderate or marginal (subclinical) deficient Mg intake generally is asymptomatic. Animal studies, however, indicate that moderate or subclinical Mg deficiency primes phagocytic cells for the release of proinflammatory cytokines leading to chronic inflammatory and oxidative stress. Human studies have found that dietary Mg ...
Source: Advances in Chronic Kidney Disease - Category: Urology & Nephrology Source Type: research
Publication date: June 2018Source: The Lancet Global Health, Volume 6, Issue 6Author(s): Ben Lacey, Sarah Lewington, Robert Clarke, Xiang Ling Kong, Yiping Chen, Yu Guo, Ling Yang, Derrick Bennett, Fiona Bragg, Zheng Bian, Shaojie Wang, Hua Zhang, Junshi Chen, Robin G Walters, Rory Collins, Richard Peto, Liming Li, Zhengming Chen, Junshi Chen, Zhengming ChenSummaryBackgroundThe age-specific association between blood pressure and vascular disease has been studied mostly in high-income countries, and before the widespread use of brain imaging for diagnosis of the main stroke types (ischaemic stroke and intracerebral haemorrh...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
Publication date: Available online 27 June 2018Source: Revista Española de Cardiología (English Edition)Author(s): Maria Mahmood, Gregory Y.H. LipAbstractBoth atrial fibrillation (AF) and chronic kidney disease (CKD) are highly prevalent, especially with increasing age and associated comorbidities, such as hypertension, diabetes, heart failure, and vascular disease. The relationship between both AF and CKD seems to be bidirectional: CKD predisposes to AF while onset of AF seems to lead to progression of CKD. Stroke prevention is the cornerstone of AF management, and AF patients with CKD are at higher risk of ...
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - Category: Cardiology Source Type: research
Publication date: Available online 31 January 2018Source: Journal of Microbiology, Immunology and InfectionAuthor(s): Ing-Kit Lee, Ching-Jung Hsieh, Chien-Te Lee, Jien-Wei LiuAbstractBackground/purposeThe impact of type 2 diabetes mellitus (DM2) on clinical severity of dengue has not been fully understood. We aimed to assess risk factors for dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) and severe dengue (SD) (defined based on the World Health Organization 1997 and 2009 dengue classifications), and additionally identify, among DM2 patients, who are at risk for developing DHF/DSS and severe dengue.MethodsA retr...
Source: Journal of Microbiology, Immunology and Infection - Category: Microbiology Source Type: research
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Chronic Kidney Disease | Research | Science | Stroke | Study | Urology & Nephrology